Molbio Diagnostics Q1 FY27 Net Profit at ₹527 Million

The Board of Directors meeting commenced at 11:47 AM and ended at 4:00 PM on September 5, 2026.

1. Approval of Financial Results

Based on Audit Committee recommendation, approved Un-Audited Standalone and Consolidated Financial Results for quarter ended June 30, 2026
Financial results subjected to limited review by statutory auditors S.R. Batliboi & Associates LLP
Standalone and Consolidated results enclosed as Annexure I

2. Authorization to Key Managerial Personnel

KMPs authorized to make appropriate disclosures to stock exchanges on timely basis
Authorized personnel:
Sriram Natarajan - Director & Chief Executive Officer (Contact: 08326724888, Email: investors@molbiodiagnostics.com)
Chandrasekhar Nair - Director-Chief Technical Officer
Manan Bimal Khokhani - Chief Financial Officer
Darshan Karekar - Company Secretary & Compliance Officer

Standalone Financials (₹ Million)

Consolidated Financials (₹ Million)

Total Income: ₹4,114.76 (Revenue from operations: ₹4,083.76, Other income: ₹31.00)
Total Expenses: ₹3,355.66
Profit Before Tax: ₹759.09
Share of Loss of Associates: ₹0.01
Tax Expenses: ₹231.65 (Current Tax: ₹285.46, Deferred Tax Credit: ₹53.81)
Profit for Period: ₹527.44
Other Comprehensive Loss: ₹3.63
Total Comprehensive Income: ₹523.81
Profit Attributable to Owners: ₹587.47
Non-controlling Interest: ₹(60.03)
Paid-up Equity Share Capital: ₹112.76
Basic EPS: ₹5.21
Diluted EPS: ₹5.21

IPO Completion

Subsequent to quarter ended June 30, 2026, company completed IPO of 11,646,246 equity shares
Includes employee reservation portion of 20,519 equity shares
Issue price: ₹807 per equity share to investors, ₹731 per equity share to employees
Fresh issue: 2,480,246 equity shares aggregating ₹2,000.00 Million
Offer for sale: 9,166,000 equity shares aggregating ₹7,396.96 Million
Equity shares listed on NSE and BSE on August 17, 2026

Employee Stock Option Plan

Shareholders approved ESOP 2025 Plan for creation of ESOP pool of 2,819,000 options
Face value: ₹1 each
No stock options granted as of June 30, 2026

Labour Code Impact

Government notified four Labour Codes on November 21, 2025
Incremental impact: Gratuity liability increased by ₹23.15 Million, Leave liability increased by ₹8.19 Million
Presented as exceptional item for year ended March 31, 2026

Income Tax Survey

Survey under Section 133A of Income-tax Act conducted during year ended March 2024
Tax demands aggregating ₹208.71 Million plus interest and penalty raised for AY 2020-21 to 2024-25
Company filed appeal with Commissioner Income Tax (Appeals)
₹78.95 Million paid under protest as of June 30, 2026
Management confident of favorable outcome, no adjustments made in financial results

Subsidiary and Associate Transactions

During FY25, company subscribed to 2,918,827 Series B preferred shares in OptraSCAN for ₹415.52 Million (19.68% equity)
During FY26, subscribed to additional 14,951,540 Series B preferred shares for ₹2,220.91 Million
Effective November 01, 2025, shareholding increased to 60%, OptraSCAN became subsidiary
During Q1 FY27, acquired additional 4.53% stake in Prognosys Medical Systems, increasing holding from 65.47% to 70.00%

Consolidated Entities

The consolidated results include:

Holding Company: Molbio Diagnostics Limited
Subsidiaries: Bigtec Private Limited, OptraSCAN INC, OptraScan India Private Limited, Prognosys Medical Systems Private Limited, Prognosys Healthcare (India) Private Limited
Associate: Chayagraphics (India) Private Limited

Subsidiaries contributed total revenues of ₹125.20 Million, total net loss after tax of ₹130.27 Million for the quarter.

Segment Information

Operating segment identified as "manufacturing of diagnostic devices, chips, reagents, etc"
Single segment operation, disclosure under Ind AS 108 not applicable

Bonus Share Allotment

During quarter ended September 30, 2025, allotted 90,207,800 bonus shares in 4:1 ratio
EPS figures for comparative periods adjusted retrospectively